<DOC>
	<DOCNO>NCT01724866</DOCNO>
	<brief_summary>The purpose study assess effect test dose HM10460A duration severe neutropenia ( DSN ) Cycle 1 patient breast cancer candidate adjuvant neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Phase 2 Study HM10460A Pegfilgrastim Use Management Neutropenia Breast Cancer Patients</brief_title>
	<detailed_description>This open label , multicenter , dose range study , sequentially enrol study dose , non-inferiority design compare effectiveness HM10460A relative fix dose pegfilgrastim concurrent active control dose HM10460A patient breast cancer . The study include 4 arm : 3 dose level HM10460A versus pegfilgrastim . The start study treatment define initiation HM10460A pegfilgrastim . The duration treatment consist maximum 4 cycle , begin Day 1 chemotherapy administration continue Day 21 . The planned number patient total 144 base 36 enrol 4 treatment arm . The target population patient breast cancer candidate neoadjuvant adjuvant treatment TC chemotherapy . All patient receive least 1 dose either HM10460A pegfilgrastim follow safety 20 ( ± 2 ) day last dose study treatment treatment-related AEs resolve return baseline/Grade 1 , whichever longer , determine outcome change follow-up .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Histologically confirm breast cancer candidate adjuvant neoadjuvant chemotherapy Candidate docetaxel cyclophosphamide chemotherapy Female male ≥ 18 year age ECOG ≤ 2 ANC ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Creatinine ≤ 1.5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL ( ≤ 25.65 μmol/L ) AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN Hemoglobin &gt; 9 g/dL Alkaline phosphatase ≤ 1.5 x ULN Known sensitivity E. coli derive product know sensitivity product administer dose Known HIV infection HBV HCV diagnosis detectable viral load immunological evidence chronic active disease Active infection serious underlie medical condition , would impair ability patient receive protocol treatment Prior bone marrow stem cell transplant Prolonged exposure glucocorticosteroids immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>